14. Segment Information

We report our operations in two operating segments: McKesson Distribution Solutions and McKesson Technology Solutions. The factors for determining the reportable segments included the manner in which management evaluates the performance of the Company combined with the nature of the individual business activities. We evaluate the performance of our operating segments on a number of measures, including operating profit before interest expense, income taxes and results from discontinued operations. Financial information relating to our reportable operating segments and reconciliations to the condensed consolidated totals is as follows:


	Quarter Ended September 30,				Six Months Ended September 30,
(In millions)	2011		2010		2011		2010
Revenues
Distribution Solutions ⁽¹⁾
Direct distribution & services	$	21,072	$	18,984	$	41,899	$	37,686
Sales to customers' warehouses		4,909		4,659		9,800		9,402
Total U.S. pharmaceutical distribution & services		25,981		23,643		51,699		47,088
Canada pharmaceutical distribution & services		2,537		2,351		5,266		4,911
Medical-Surgical distribution & services		873		770		1,604		1,456
Total Distribution Solutions		29,391		26,764		58,569		53,455
Technology Solutions
Services		643		604		1,273		1,199
Software & software systems		153		138		297		273
Hardware		29		28		57		57
Total Technology Solutions		825		770		1,627		1,529
Total	$	30,216	$	27,534	$	60,196	$	54,984
Operating profit
Distribution Solutions ⁽²⁾	$	477	$	491	$	952	$	996
Technology Solutions ⁽³⁾		108		14		208		78
Total		585		505		1,160		1,074
Corporate		(101)		(85)		(196)		(171)
Interest Expense		(64)		(44)		(128)		(87)
Income from Continuing Operations Before Income Taxes	$	420	$	376	$	836	$	816

⁽¹⁾Revenues derived from services represent less than 2% of this segment's total revenues for the quarters and six months ended September 30, 2011 and 2010.

⁽²⁾Operating profit includes AWP litigation charges of $118 million for the quarter and six months ended September 30, 2011 and $24 million for the quarter and six months ended September 30, 2010, which were recorded in operating expenses. Operating profit for the six months ended September 30, 2010 includes the receipt of $51 million representing our share of a settlement of an antitrust class action lawsuit brought against a drug manufacturer, which was recorded as a reduction to cost of sales.

⁽³⁾Operating profit for the quarter and six months ended September 30, 2010 includes a $72 million asset impairment charge for capitalized software held for sale, which was recorded in cost of sales.